reviewed april 2026|next review october 2026|88 physicians psi has verified|88 published studies
Selank
Selank is a synthetic heptapeptide analog of tuftsin (a naturally occurring immune peptide) registered as a prescription anxiolytic by the Russian Federation Ministry of Health in 2009, combining anxiolytic and immunomodulatory activity without the sedation or dependence risk of benzodiazepines.
Evidence landscape: 88 published studies
88 published items. 6 human studies and 78 animal studies. Evidence base is stronger than many research peptides but concentrated in Russian-language literature.
- 6 Human
- 78 Animal
- 4 Reviews
Registered as a prescription anxiolytic in Russia (approved 2009). Not FDA-approved. Placed on the FDA's Category 2 list (a designation that temporarily prevented licensed pharmacies from preparing this compound), meaning licensed pharmacies could not prepare it. It is expected to return to Category 1 (legal for pharmacy preparation) following the February 2026 HHS announcement.
Russian clinical data supports anxiolytic efficacy. BDNF upregulation and immune modulation documented in animal study models. No Western-standard randomized controlled trials.
One of a handful of peptides with regulatory approval in any country for a psychiatric indication. Non-sedating and non-addictive profile distinguishes it from benzodiazepines.
PSI Assessment
Registered as a prescription anxiolytic by the Russian Federation Ministry of Health in 2009, Selank is one of a handful of peptides that holds regulatory approval in any country for a psychiatric indication. It is a synthetic analog of tuftsin, an immune peptide, engineered to combine anxiolytic and immunomodulatory activity without the sedation or dependence risk of benzodiazepines. The Russian clinical data supports anxiolytic efficacy. The limitation: Western-standard randomized controlled trials have not been conducted, and much of the published literature is in Russian-language journals.
Registered as a prescription anxiolytic in Russia. Non-sedating and non-addictive. No Western-standard randomized controlled trials.
The mechanism has two arms. The anxiolytic arm modulates GABAergic tone and increases BDNF (brain-derived neurotrophic factor) expression in the hippocampus and frontal cortex, pathways linked to neuroplasticity and mood regulation. The immunomodulatory arm, inherited from the tuftsin backbone, affects cytokine balance and immune cell activity. Intranasal delivery allows partial bypass of the blood-brain barrier.
What the evidence supports
Selank reduces anxiety-related behavior in animal models consistently across multiple studies. It increases BDNF expression in the hippocampus and frontal cortex. It modulates immune function through tuftsin-derived pathways. It is registered as a prescription anxiolytic in Russia with clinical data supporting the approved indication. The non-sedating, non-addictive profile distinguishes it from benzodiazepines.
What is not yet established
Whether Selank's anxiolytic effects are clinically significant by Western randomized controlled trial standards. The optimal dose and route for cognitive enhancement. Whether the immune effects translate to meaningful clinical outcomes. Long-term safety data. Independent replication of Russian clinical findings in Western trial settings.
Research Evidence
The findings below cover the Russian clinical data, the dual mechanism, and the difference between Russian regulatory approval and Western clinical trial standards.
Evidence by condition
Evidence dimensions across Selank indications. Anxiety has Russian regulatory support. Cognitive and immune indications lack controlled human data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Anxiety | ||||
| Cognitive Enhancement | ||||
| Immune Modulation | ||||
| Neuroprotection |
Selank is registered as a prescription anxiolytic in Russia with published clinical data showing anxiolytic effects comparable to low-dose benzodiazepines without sedation, tolerance, or dependence.
Russian regulatory approval is meaningful but the approval data has not been independently verified by international regulatory bodies. Western-standard randomized controlled trials have not been conducted.
Selank increases BDNF (brain-derived neurotrophic factor) expression in the hippocampus and frontal cortex. BDNF upregulation is an established pathway for anxiolytic and antidepressant effects across multiple drug classes.
The BDNF mechanism is biologically plausible and well-characterized. Whether the magnitude of BDNF increase from Selank is clinically significant in humans has not been established in controlled trials.
Gene expression studies show Selank affects 84 genes related to immune and neurological function. The tuftsin-derived immunomodulatory pathway is distinct from the anxiolytic mechanism.
The dual mechanism (anxiolytic plus immune modulation) is scientifically distinctive. Whether the immune effects translate to meaningful clinical outcomes has not been established.
6 Human|78 Animal|4 Reviews
View all 88 indexed studiesHow Selank Works
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic derivative of the immunopeptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro tripeptide that increases metabolic stability. It modulates GABAergic tone indirectly, increases BDNF expression, and affects the balance of enkephalin and monoamine metabolism in the brain.
Selank works like a calming signal for your brain's anxiety circuits, but without the sedation or addiction risk of traditional anti-anxiety medications. It modulates the same inhibitory pathways as benzodiazepines but through a different, gentler mechanism. It also has immune-supporting properties because it is based on a natural immune peptide.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Selank modulates the GABAergic system, the brain's primary inhibitory neurotransmitter network, producing anxiolytic effects without the sedation or dependence associated with benzodiazepines. It also influences serotonin and norepinephrine metabolism, which may contribute to mood stabilization. As a tuftsin analog, it retains immunomodulatory properties, affecting cytokine balance and immune cell activity. The intranasal delivery route allows the peptide to bypass the blood-brain barrier partially, reaching CNS targets more directly.
What is Selank being studied for?
Researchers are studying Selank across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Selank overall. This means a compound can have human studies for one condition but only animal data for another.
Anxiety
·Human TrialsAnimal studies consistently show anxiolytic effects comparable to benzodiazepines without sedation or dependence. Selank is approved in Russia for generalized anxiety disorder.
Limitations: No Western-standard randomized controlled trials. The Russian approval data has not been independently verified by international regulatory bodies.
Cognitive Enhancement
·Animal StudiesAnimal data shows improved memory consolidation and learning, likely through BDNF upregulation and enkephalin modulation.
Limitations: Cognitive effects may be secondary to anxiety reduction rather than direct nootropic action. No controlled Western trials for cognitive endpoints.
Immune Modulation
·Animal StudiesThe tuftsin backbone gives Selank immunomodulatory properties. It influences IL-6, interferons, and T-cell function.
Limitations: Whether the immune effects translate to meaningful clinical outcomes (infection resistance, autoimmune modulation) is not established.
Neuroprotection
·PreclinicalAnimal models (animal studies) show protection against neurotoxicity and ischemic brain injury. The BDNF pathway is the proposed mechanism.
Limitations: Entirely from animal studies. No human neuroprotection data.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Registered as a prescription anxiolytic in Russia (approved 2009). Placed on the FDA's Category 2 list (a designation that temporarily prevented licensed pharmacies from preparing this compound), meaning licensed pharmacies could not prepare it. It is expected to return to Category 1 (legal for pharmacy preparation) following the February 2026 HHS announcement.
Availability: Available in Russia as a prescription nasal spray. In the United States, available through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient, pending reclassification to legal pharmacy preparation status.
Class context: Synthetic tuftsin analog. Semax is a nootropic peptide from the same Russian development program. DSIP (delta sleep-inducing peptide) is a sleep/stress peptide with a different mechanism.
Used clinically in Russia with a favorable reported safety profile. Does not cause sedation, dependence, or withdrawal. Intranasal administration avoids first-pass metabolism. Western clinical trial safety data is limited.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Selank discussion.
Comparison and Related Research
Selank is most often compared with other neuropeptides and anxiolytic compounds. The comparisons below outline how each differs in mechanism, evidence depth, and regulatory status.
Head-to-head comparisons
Full research comparisons covering Selank and another peptide side by side.
Selank vs Semax
Research comparison of selank and semax, two Russian-developed neuropeptides for cognitive and anxiolytic research. Mechanisms, evidence levels, clinical backgrounds, and limitations analyzed.
View full comparisonSelank vs DSIP
DSIP targets sleep architecture. Selank targets anxiety through GABA. Both used for relaxation but through different mechanisms. Evidence-graded comparison.
View full comparisonSelank vs NA-Selank
NA-Selank is the N-acetyl form with potentially better nasal absorption. Selank is the original with more research. What the modification changes.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Animal study demonstrating that selank improved learning and memory performance in a conditioned avoidance task. Rats treated with the peptide showed optimized adaptive behavior under stress, supporting the anxiolytic and nootropic profile reported in earlier preclinical work.Kozlovskii II & Danchev ND, 2003 in Neurosci Behav Physiol. View on PubMed
- 2.Study showing selank reduced ethanol-induced hyperactivity and behavioral sensitization in mice. The findings suggested the peptide may modulate reward-related behaviors, adding to the body of research on its effects on anxiety and stress-related pathways.Kolik LG et al., 2016 in Bull Exp Biol Med. View on PubMed
- 3.Human study examining immune system changes in patients with anxiety-related conditions who received selank. The research documented shifts in immune markers alongside the anxiolytic effects, suggesting a dual mechanism affecting both neurological and immune function.Uchakina ON et al., 2008 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
- 4.Clinical study testing selank in patients with generalized anxiety disorder and neurasthenia. The trial reported anxiolytic effects comparable to a benzodiazepine reference, with investigators proposing mechanisms involving serotonin metabolism and BDNF expression.Zozulia AA et al., 2008 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.